172 related articles for article (PubMed ID: 12644587)
1. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
Moufarij MA; Phillips DR; Cullinane C
Mol Pharmacol; 2003 Apr; 63(4):862-9. PubMed ID: 12644587
[TBL] [Abstract][Full Text] [Related]
2. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
3. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
4. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
Crul M; van Waardenburg RC; Bocxe S; van Eijndhoven MA; Pluim D; Beijnen JH; Schellens JH
Biochem Pharmacol; 2003 Jan; 65(2):275-82. PubMed ID: 12504803
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
6. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
[TBL] [Abstract][Full Text] [Related]
8. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG
Int J Gynecol Cancer; 2005; 15 Suppl 1():18-22. PubMed ID: 15839954
[TBL] [Abstract][Full Text] [Related]
11. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
Zhen W; Link CJ; O'Connor PM; Reed E; Parker R; Howell SB; Bohr VA
Mol Cell Biol; 1992 Sep; 12(9):3689-98. PubMed ID: 1380646
[TBL] [Abstract][Full Text] [Related]
12. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Yang LY; Li L; Jiang H; Shen Y; Plunkett W
Clin Cancer Res; 2000 Mar; 6(3):773-81. PubMed ID: 10741696
[TBL] [Abstract][Full Text] [Related]
13. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids.
Besançon OG; Tytgat GA; Meinsma R; Leen R; Hoebink J; Kalayda GV; Jaehde U; Caron HN; van Kuilenburg AB
Cancer Lett; 2012 Jun; 319(1):23-30. PubMed ID: 22182450
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
17. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*).
Moorehead RA; Armstrong SG; Rainbow AJ; Singh G
Cancer Chemother Pharmacol; 1996; 38(3):245-53. PubMed ID: 8646799
[TBL] [Abstract][Full Text] [Related]
20. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
